Laddar...
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity
OBJECTIVE: Letrozole is a non-steroidal aromatase inhibitor (AI) used to treat hormone receptor positive (HR+) breast cancer. Variability in letrozole efficacy and toxicity may be partially attributable to variable systemic drug exposure, which may be influenced by germline variants in the enzymes r...
Sparad:
| I publikationen: | Pharmacogenet Genomics |
|---|---|
| Huvudupphovsmän: | , , , , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8185249/ https://ncbi.nlm.nih.gov/pubmed/34096894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/FPC.0000000000000429 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|